The Increasing Prevalence of Organ Transplantation Drives the Antibody-mediated Rejection Market
Antibody-mediated rejection refers to the rejection of transplanted organs by pre-formed donor-specific antibodies. Antibodies are proteins produced by the immune system to help protect the body from foreign substances. The immune system identifies transplanted organs as foreign and tries to attack and destroy them by producing antibodies against them. Antibody-mediated rejection poses a major challenge during organ transplantation and often leads to premature graft failure if left untreated.
The antibody-mediated rejection market is estimated to be valued at USD 126.5 Mn in 2024 and is expected to reach USD 291.1 Mn by 2031, growing at a compound annual growth rate (CAGR) of 12.64% from 2024 to 2031.
Furthermore, political instability and conflicts in several parts of world have led to economic uncertainties. This can reduce the ability and priority of governments as well as patients to invest in high-cost antibody-mediated rejection therapies and transplants. Antibody-mediated Rejection Market players must explore strategies like value-based pricing, outcomes-based contracts and partnerships with local healthcare systems to improve affordability of their solutions.
Get More Insights On- Antibody-mediated Rejection Market
Get This Report in Japanese Language: 抗体介在性拒絶反応市場
Get This Report in Korean Language: 항체 매개 거부 시장
English
Arabic
Français
Español
Português
Deutsch
Dutch
Italiano
Russian
Romaian